Dual pathway inhibition of coagulation and inflammation with rivaroxaban: a new therapy paradigm against atherosclerosis : Journal of Cardiovascular Pharmacology

Journal Logo

Commentary

Dual pathway inhibition of coagulation and inflammation with rivaroxaban: a new therapy paradigm against atherosclerosis

Testa, Alberto1; Morello, Alberto MD2,3; Corcione, Nicola MD2,3; Biondi-Zoccai, Giuseppe MD, MStat4,5

Author Information
Journal of Cardiovascular Pharmacology ():10.1097/FJC.0000000000001385, January 12, 2023. | DOI: 10.1097/FJC.0000000000001385
  • Free
  • PAP
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.